Key Highlights:
- Bristol-Myers Squibb (BMY, Financial) boosts annual guidance after surpassing Q1 2025 earnings estimates.
- The oncology segment showcases significant growth, with key products like Eliquis and Revlimid surpassing expectations.
- Analysts project a potential upside of over 17%, reflecting strong future prospects.
Bristol-Myers Squibb Co. (BMY) saw a notable rise in its stock price, propelled by impressive first-quarter 2025 earnings that exceeded expectations. The pharmaceutical giant also revised its annual guidance upwards, buoyed by favorable forex impacts. Driven by the remarkable performance of flagship products like Eliquis and Revlimid, the company achieved a substantial $11.2 billion in revenue. Additionally, the oncology segment demonstrated robust growth, led by therapies such as Opdivo.
Wall Street Analysts' Insights
According to forecasts from 22 financial analysts, Bristol-Myers Squibb Co (BMY, Financial) has a one-year average target price of $56.89. The predicted range varies from a high of $70.00 to a low of $33.10, reflecting a potential upside of 17.22% from its current trading price of $48.53. For more comprehensive insights, visit the Bristol-Myers Squibb Co (BMY) Forecast page.
The consensus among 28 brokerage firms rates Bristol-Myers Squibb Co's (BMY, Financial) stock as a "Hold," with an average recommendation score of 2.7 on a scale where 1 signifies a Strong Buy and 5 indicates a Sell.
Valuation Analysis and Future Prospects
GuruFocus projects the GF Value of Bristol-Myers Squibb Co (BMY, Financial) over the next year to be $63.10. This valuation suggests a notable upside potential of 30.02% from its current stock price of $48.53. The GF Value represents an estimation of the stock's fair trading value, taking into account its historical trading multiples, past business growth, and future performance predictions. Investors can explore further details on the Bristol-Myers Squibb Co (BMY) Summary page.
